vTv Therapeutics (VTVT) Income towards Parent Company (2014 - 2026)

vTv Therapeutics has disclosed Income towards Parent Company across 13 years of filings, most recently posting $24.1 million for Q1 2026.

• Income towards Parent Company for Q1 2026 came in at $24.1 million, up 488.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$729000.0 (up 96.82% YoY), and the FY2025 annual result was -$31.1 million, down 36.89% from the prior year.
• Income towards Parent Company came in at $24.1 million for Q1 2026 at vTv Therapeutics, up from -$7.1 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $24.1 million in Q1 2026 to a low of -$10.3 million in Q3 2025.
• The 5-year median for Income towards Parent Company is -$6.1 million (2022), against an average of -$4.7 million.
• Across the five-year window, Income towards Parent Company sank 386.44% in 2022 and jumped 488.19% in 2026, its largest moves.
• vTv Therapeutics' Income towards Parent Company stood at -$6.1 million in 2022, then advanced by 27.08% to -$4.4 million in 2023, then rose by 0.09% to -$4.4 million in 2024, then slumped by 60.87% to -$7.1 million in 2025, then jumped by 438.11% to $24.1 million in 2026.
• The last three Income towards Parent Company figures came in at $24.1 million (Q1 2026), -$7.1 million (Q4 2025), and -$10.3 million (Q3 2025), per Business Quant data.